0001104659-16-161134.txt : 20161208 0001104659-16-161134.hdr.sgml : 20161208 20161208070105 ACCESSION NUMBER: 0001104659-16-161134 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161207 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20161208 DATE AS OF CHANGE: 20161208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Corvus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001626971 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464670809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37719 FILM NUMBER: 162040348 BUSINESS ADDRESS: STREET 1: 863 MITTEN ROAD STREET 2: SUITE 102 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: (650) 900-4520 MAIL ADDRESS: STREET 1: 863 MITTEN ROAD STREET 2: SUITE 102 CITY: BURLINGAME STATE: CA ZIP: 94010 8-K 1 a16-22874_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 7, 2016

 

 

CORVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-37719

 

46-4670809

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

 

863 Mitten Road, Suite 102
Burlingame, CA 94010
 (Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (650) 900-4520

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 7, 2016, the Board of Directors (the “Board”) of Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”), approved, on recommendation of the Compensation Committee of the Board, increases to the 2017 annual salaries for each of the Company’s Chief Financial Officer, Vice President, Pharmaceutical Development, and Vice President, Chemistry Research, as well as new stock awards for such executive officers and the Company’s Chief Executive Officer.  The stock option awards to each of the executive officers will be granted effective as of the close of business on December 7, 2016 with an exercise price equal to the closing price of the Company’s common stock as reported on The NASDAQ Global Market on the date of grant. The awards will be made pursuant to the Company’s 2016 Equity Incentive Award Plan and will vest in equal monthly installments over 48 months, subject to continued service as of each vesting date.

 

The following table sets forth the 2017 annual salaries and number of shares underlying the stock option awards for each of the named executive officers and principal financial officer:

 

Name and Principal Position

 

2017 Salary
($)

 

Stock Option Award
(shares)

 

Richard A. Miller, M.D.

 

$

300,000

 

160,000

 

Chief Executive Officer

 

 

 

 

 

Leiv Lea

 

$

291,500

 

25,000

 

Chief Financial Officer

 

 

 

 

 

William B. Jones, Ph.D.

 

$

265,000

 

25,000

 

Vice President, Pharmaceutical Development

 

 

 

 

 

Erik J. Verner, Ph.D.

 

$

250,000

 

25,000

 

Vice President, Chemistry Research

 

 

 

 

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CORVUS PHARMACEUTICALS, INC.

 

 

Date: December 8, 2016

By:

/s/ Leiv Lea

 

 

Leiv Lea

 

 

Chief Financial Officer

 

3